John Schmid
Direktor/Vorstandsmitglied bei XERIS BIOPHARMA HOLDINGS, INC.
Vermögen: 741 238 $ am 30.04.2024
Profil
Mr. John P.
Schmid is a Lead Independent Director at Xeris Biopharma Holdings, Inc., an Independent Director at Design Therapeutics, Inc., an Independent Director at Poseida Therapeutics, Inc., an Independent Director at AnaptysBio, Inc., a Chairman at Speak, Inc. and an Independent Director at Helix Acquisition Corp.
II.
He is on the Board of Directors at Xeris Biopharma Holdings, Inc., Design Therapeutics, Inc., Poseida Therapeutics, Inc., Forge Therapeutics, Inc., AnaptysBio, Inc. and Helix Acquisition Corp.
II.
Mr. Schmid was previously employed as an Independent Director by Helix Acquisition Corp., an Independent Non-Executive Director by Xeris Pharmaceuticals, Inc., an Independent Director by Neos Therapeutics, Inc., a Chief Financial Officer by Auspex Pharmaceuticals, Inc., a Chief Financial Officer & Secretary by Trius Therapeutics, Inc., a Chief Financial Officer by GeneFormatics, Inc., a Chief Financial Officer by Endonetics, Inc., a President & Director by San Diego Venture Group, an Associate by Idanta Partners Ltd., a Vice President by Home Federal Savings & Loan Association (Nampa, Idaho), a Chief Financial Officer by Allylix, Inc., a Chief Financial Officer by Cengent Therapeutics, Inc., a Vice President by Indiana Bank & Trust Co., and a Chief Financial Officer by Vessix Vascular, Inc. He also served on the board at Patara Pharma LLC.
He received his undergraduate degree from Wesleyan University and an MBA from the University of San Diego.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,18% | 09.02.2024 | 30 000 ( 0,18% ) | 308 700 $ | 30.04.2024 |
| 31.03.2024 | 57 639 ( 0,10% ) | 216 723 $ | 30.04.2024 | |
| 10.05.2024 | 79 559 ( 0,05% ) | 135 250 $ | 30.04.2024 | |
| 15.06.2023 | 39 300 ( 0,04% ) | 80 565 $ | 30.04.2024 | |
ANAPTYSBIO, INC.
-.--% | 01.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von John Schmid
| Unternehmen | Position | Beginn |
|---|---|---|
| ANAPTYSBIO, INC. | Direktor/Vorstandsmitglied | 30.06.2015 |
| POSEIDA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.07.2018 |
| DESIGN THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.11.2020 |
| XERIS BIOPHARMA HOLDINGS, INC. | Direktor/Vorstandsmitglied | 05.10.2021 |
Forge Therapeutics, Inc.
 Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 16.05.2017 |
Speak, Inc.
 Speak, Inc. Miscellaneous Commercial ServicesCommercial Services Speak, Inc. operates as a speaker bureau. | Vorsitzender | 21.12.2013 |
Ehemalige bekannte Positionen von John Schmid
| Unternehmen | Position | Ende |
|---|---|---|
| HELX ACQU | Direktor/Vorstandsmitglied | 01.04.2022 |
Xeris Pharmaceuticals, Inc.
 Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | Direktor/Vorstandsmitglied | 05.10.2021 |
| NEOS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.03.2021 |
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von John Schmid
| University of San Diego | Masters Business Admin |
| Wesleyan University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ANAPTYSBIO, INC. | Health Technology |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| DESIGN THERAPEUTICS, INC. | Health Technology |
| XERIS BIOPHARMA HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 17 |
|---|---|
Allylix, Inc.
 Allylix, Inc. Pharmaceuticals: OtherHealth Technology Allylix, Inc. develops terpene products for flavor and fragrance, food ingredients, pharmaceuticals, agricultural, and biofuels markets. The company was founded by Joseph Chappel, Thomas E. Jurgensen, and Joseph Noel on January 4, 2005 and is headquartered in Lexington, KY. | Health Technology |
San Diego Venture Group
 San Diego Venture Group Financial ConglomeratesFinance San Diego Venture Group operates as a non-profit organization that engages in the funding of start up companies. it focuses on the provision of support to the venture capital eco-system. It serves entrepreneurs, venture capitalists, community leaders, and business advisors. The company was founded in 1986 and is headquartered in San Diego, CA. | Finance |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
| Indiana Bank & Trust Co. | Finance |
Cengent Therapeutics, Inc.
 Cengent Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cengent Therapeutics, Inc. used to research and develop pharmaceutical drugs. It was a structure-based drug discovery company with a primary focus on compounds targeting signal transduction for the treatment of obesity and diabetes. It used to discover orally active PTP-1B inhibitors for treatment of type II diabetes and obesity. It was headquartered in San Diego, CA. | Commercial Services |
Vessix Vascular, Inc.
 Vessix Vascular, Inc. Pharmaceuticals: OtherHealth Technology Vessix Vascular, Inc. develops products to treat artery disease. The company was founded in 2003 and is headquartered in Laguna Hills, CA. | Health Technology |
| GeneFormatics, Inc. | Health Technology |
Endonetics, Inc.
 Endonetics, Inc. Medical SpecialtiesHealth Technology Endonetics, Inc. develops technologies for the diagnosis and treatment of gastroesophageal reflux disease | Health Technology |
Idanta Partners Ltd.
 Idanta Partners Ltd. Investment ManagersFinance Idanta Partners Ltd (Idanta Partners) is a venture capital firm founded in 1971 by Dave Dunn. The firm is headquartered in San Diego. | Finance |
Home Federal Bank (Nampa, Idaho)
 Home Federal Bank (Nampa, Idaho) Major BanksFinance Home Federal Bank provides banking services. It provides personal, trust & management, business and loan banking services. It has offices in Aberdeen, Brandon, Canton, Colman, Freeman, Harrisburg, Hartford, Lennox and Marshall. The company is located in Boise, ID. | Finance |
Speak, Inc.
Speak, Inc. Miscellaneous Commercial ServicesCommercial Services Speak, Inc. operates as a speaker bureau. | Commercial Services |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA. | Health Technology |
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
Patara Pharma LLC
 Patara Pharma LLC Pharmaceuticals: MajorHealth Technology Patara Pharma LLC provides biotechnology solutions. It develops biopharmaceutical therapy for the treatment of allergic and inflammatory diseases and conditions that affect orphan patient populations. The company was founded by William Gerhart, Pravin Soni and Ahmet Tutuncu in 2013 and is headquartered in San Diego, CA. | Health Technology |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | Health Technology |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | Health Technology |
Helix Acquisition Corp.
 Helix Acquisition Corp. Financial ConglomeratesFinance Helix Acquisition Corp. operates as a blank check company. It is a special purpose acquisition company which is incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 13, 2020 and is headquartered in Boston, MA. | Finance |
